ly3437943 retatrutide triple agonist glp-1 gip glucagon is drawing major attention in metabolic and liver research., Researchers are studying how receptor agonism (GIP / / glucagon) may influence:, • Liver fat metabolism, • Energy Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals

The peptide appears to work through direct effects on growth factor receptor expression [11]

Biggest Impact: The largest potential for prevention was seen in breast and endometrial cancers for women, and in kidney and liver cancers for both men and women

MHRA Yellow Card Data: Breaking Down the Reports Key Statistics By mid-2025, the Yellow Card scheme recorded 1,143 pancreatitis reports (acute/chronic) for semaglutide and tirzepatide, with 17 fatalities

Lana Rodriguez said semaglutide is the best thing that's ever happened to her